Compare ADMA Biologics Inc (ADMA) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Fortinet Inc — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Fortinet Inc trades at $155.89 (market cap $116.25B). The key difference: Fortinet Inc is far larger — about 54.6× ADMA Biologics Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FTNT | |
|---|---|---|
Market Cap | $2.13B | $116.25B |
Sector | Health | Technology |
52-Week High | $20.38 | $162.35 |
52-Week Low | $7.60 | $74.39 |
Enterprise Value | $2.20B | $113.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Fortinet (FTNT) trades at $158.67, up 1.55% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with revenue growing to $6.80B in 2025 and net income of $1.85B, though valuation multiples like P/E of 62.93 appear elevated. Recent earnings have consistently beaten expectations, and the company maintains robust profitability with a gross margin of 80.3%. News highlights include AI-driven security growth and upcoming Q2 2026 results announcement on July 29, 2026.
The outlook remains positive due to strong execution and cybersecurity demand, but high valuation and competitive pressures pose risks. Analyst consensus is mixed with a $115.53 price target below current levels, suggesting caution despite bullish technicals. Key risks include execution missteps and market volatility, while institutional sentiment leans neutral with 47.06% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
